Skip to main content
logo
CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
2.180
-0.050 (-2.24%)
Nov 3, 2026, 4:00 PM EST - Market closed

CytomX Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
18.376.2138.1101.2153.1637.31
Revenue Growth
-87.03%-44.82%36.45%90.38%42.48%-45.47%
Gross Profit
18.376.2138.1101.2153.1637.31
Operating Income
-87.15-19.5625-6.48-93.84-116.04
Net Income
-82.66-20.3731.87-0.57-99.32-115.87
Earnings Per Share
-0.45-0.150.38-0.01-1.51-1.81
EPS Growth
------

Cash & Debt
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
330.28137.05100.62174.51193.65305.23
Total Debt
5.74.249.3913.9718.0621.67
Net Cash (Debt)
324.58132.8191.24160.54175.59283.55
Net Cash Growth
114.66%45.57%-43.17%-8.58%-38.07%-2.64%
Net Cash Per Share
1.770.961.082.182.674.42

Cash Flow & CapEx
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-82.41-75.59-86.23-56.04-110.79-119.03
Capital Expenditures
-0.07-0.22-0.31-0.84-1.74-1.61
Free Cash Flow
-82.48-75.81-86.54-56.88-112.53-120.64
Free Cash Flow Growth
------

Margins
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-476.17%-25.67%18.10%-6.41%-176.50%-311.00%
Pretax Margin
-433.93%-22.48%23.24%3.28%-186.82%-310.54%
Profit Margin
-451.59%-26.73%23.08%-0.56%-186.82%-310.54%
FCF Margin
-450.65%-99.48%-62.66%-56.19%-211.67%-323.33%

Valuation
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingNov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
--2.53---
Forward PE
-3.0347.9916.30--
PS Ratio
25.959.470.581.031.997.57